30.40

4.04% 1.18

After Hours: 30.87 0.47 +1.55%

Bicara Therapeutics Inc (BCAX)

Overview News Price History Discussions Forecast

Bicara Therapeutics Inc stock is traded at $30.40, with a volume of 1.84M. It is up +4.04% in the last 24 hours and up +52.00% over the past month. Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Previous Close:

$29.22

Open:

$29.45

24h Volume:

1.84M

Relative Volume:

2.68

Market Cap:

$2.00B

Revenue:

Net Income/Loss:

$-137.95M

P/E Ratio:

-12.05

EPS:

-2.5226

Net Cash Flow:

$-107.11M

1W Performance:

+2.39%

1M Performance:

+52.00%

6M Performance:

+77.05%

1Y Performance:

+237.40%

1-Day Range:

$29.06

$30.99

1-Week Range:

$28.62

$30.99

52-Week Range:

$8.98

$30.99

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name

Bicara Therapeutics Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

617-468-4219

Address

116 HUNTINGTON AVENUE SUITE 703, BOSTON

Employee

103

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

BCAX's Discussions on Twitter

Compare BCAX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCAX Bicara Therapeutics Inc	30.40	1.92B	0	-137.95M	-107.11M	-2.5226
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-26	Initiated	BofA Securities	Buy
Jan-29-26	Initiated	Citizens JMP	Mkt Perform
Jan-08-26	Initiated	BTIG Research	Buy
Dec-18-25	Initiated	Mizuho	Neutral
Aug-19-25	Initiated	Piper Sandler	Overweight
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight
Apr-17-25	Initiated	Wells Fargo	Underweight
Feb-06-25	Initiated	Wedbush	Outperform
Dec-06-24	Initiated	H.C. Wainwright	Buy
Nov-05-24	Initiated	Rodman & Renshaw	Buy
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight
Oct-08-24	Initiated	Morgan Stanley	Overweight
Oct-08-24	Initiated	Stifel	Buy
Oct-08-24	Initiated	TD Cowen	Buy

View All

Bicara Therapeutics Inc Stock (BCAX) Latest News

11:22 AM

Bicara Therapeutics Inc stock hits all-time high at 29.92 USD - Investing.com

11:22 AM

Jul 03, 2026

Price to earnings forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView

Jul 03, 2026

Jul 02, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 02, 2026

Jul 01, 2026

Citizens upgrades Bicara Therapeutics stock price target on CRC data - Investing.com UK

Jul 01, 2026

Citizens upgrades Bicara Therapeutics stock price target on CRC data By Investing.com - Investing.com South Africa

Jul 01, 2026

Jun 30, 2026